Sun Pharma Corporate Overview

Our Specialty Portfolio Ilumya/ Ilumetri - Indication For plaque psoriasis SUN PHARMA • Launched in US in October 2018 & in Australia in Dec-2018, Phased launch in Europe by Almirall starting December 2018 onwards. • Long term clinical data shows that the significant response rate seen in 52 & 64 weeks were maintained over five years • Evaluating new indications for Ilumya - Phase-2 data shows potential to improve joint & skin symptoms of Psoriatic Arthritis. Commenced Phase-3 in 2020 • Out licensed to CMS for Greater China market & to Hikma for Middle East & North African markets Launched in Japan in September 2020 . • Indication - For dry eye disease Cequa • Launched in US in October 2019 Absorica LD Levulan Kerastick • Out-licensed to CMS for Greater China market in June 2019 •Indication - For the treatment of severe recalcitrant nodular acne that cannot be cleared up by any other acne treatments, including antibiotics. • Launched in US in Feb-2020 • Indication - In combination with BLU-U (Blue Light Photodynamic Therapy Illuminator) for treatment of minimally to moderately thick actinic keratoses of the face, scalp, or upper extremities. •Currently marketed in US for actinic keratosis © Sun Pharmaceutical Industries Limited. All Rights Reserved. 8

View entire presentation